Section 182 of the Trade Act of 1974, known as the “Special 301” provisions, requires the United States Trade Representative to identify countries that deny adequate and effective intellectual property protections or fair and equitable market access to U.S. persons who rely on IP protection. As part of the 2021 Special 301 Review process conducted by USTR, Justin Pine, J.D., Senior Director of International Affairs, prepared BIO’s formal submission to USTR and the interagency Special 301 subcommittee highlighting the IP issues facing our members in key markets around the world.
In addition to addressing systemic IP challenges abroad, BIO’s 2021 Special 301 Review Submission highlights how IP is critical to supporting BIO’s Vision, Mission, and Purpose as an enabler of biotech innovation. This year’s submission also illustrates the critical role of IP as a tool to defeat COVID-19 and as a driver of economic growth and recovery in the post-pandemic world.
The U.S. Biotech Crops Alliance appreciates the opportunity to provide comments in response to USTR’s Request for Comments on negotiating objectives regarding modernization of the North American Free Trade Agreement with Canada and Mexico (82 FR…
The Biotechnology Innovation Organization (BIO) appreciates the opportunity to respond to the U.S. Trade Representative’s (USTR) request for comments on negotiating objectives to modernize the North American Free Trade Agreement (NAFTA).
BIO applauds the Subcommittee for examining trade policy and priorities to support agricultural producers, promote innovation, protect the environment and enable agriculture to combat climate change.
Because of bipartisan support, for over twenty…
.png){kind=logo}
Section 182 of the Trade Act of 1974, known as the “Special 301” provisions, requires the United States Trade Representative to identify countries that deny adequate and effective intellectual property protections or fair and equitable market access to U.S. persons who rely on IP protection. As part of the 2021 Special 301 Review process conducted by USTR, Justin Pine, J.D., Senior Director of International Affairs, prepared BIO’s formal submission to USTR and the interagency Special 301 subcommittee highlighting the IP issues facing our members in key markets around the world.
In addition to addressing systemic IP challenges abroad, BIO’s 2021 Special 301 Review Submission highlights how IP is critical to supporting BIO’s Vision, Mission, and Purpose as an enabler of biotech innovation. This year’s submission also illustrates the critical role of IP as a tool to defeat COVID-19 and as a driver of economic growth and recovery in the post-pandemic world.